Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114693 | 0.91 | MTNR1A (0.57) | MTNR1AKMT2APARP1ENPP1DAO | |
| SCHEMBL31726590 | 0.78 | PARP1 (0.59) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL13663043 | 0.78 | PARP1 (0.59) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL2127227 | 0.77 | MTNR1A (0.62) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL15485039 | 0.75 | MTNR1A (0.53) | MTNR1AKMT2APARP1SLC22A12 | |
| SCHEMBL28922916 | 0.74 | MTNR1A (0.59) | MTNR1AKMT2APARP1ENPP1DAO | |
| SCHEMBL7824667 | 0.74 | MTNR1A (0.59) | MTNR1APARP1ENPP1DAOSLC22A12 | |
| SCHEMBL28184833 | 0.74 | MTNR1A (0.58) | MTNR1APARP1DAOSLC22A12L3MBTL1 | |
| SCHEMBL3592491 | 0.74 | MTNR1A (0.52) | MTNR1AKMT2APARP1DAOSLC22A12 | |
| SCHEMBL15491685 | 0.72 | MTNR1A (0.53) | MTNR1APARP1DAOSLC22A12L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | MTNR1A 583/4885KMT2A 3866/4885PARP1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.